Whitehawk Therapeutics, Inc. 8-K

What Happened

• Whitehawk Therapeutics, Inc. held its annual meeting of stockholders on June 11, 2026 and reported the voting results in an 8-K filed June 12, 2026. A total of 40,375,023 shares were present in person or by proxy (about 82% of voting power as of the April 17, 2026 record date), constituting a quorum.
• Three Class III directors were elected to serve until the 2029 annual meeting: Behzad Aghazadeh, Ph.D. (For: 26,666,124; Withheld: 5,867,225; Broker non-votes: 7,841,674), Richard Maroun (For: 27,701,332; Withheld: 4,832,017; Broker non-votes: 7,841,674), and Emma Reeve (For: 27,704,564; Withheld: 4,828,785; Broker non-votes: 7,841,674).
• On an advisory (non-binding) vote to approve named executive officer compensation, shareholders voted For: 22,896,061; Against: 6,013,600; Abstentions: 3,623,688; Broker non-votes: 7,841,674 (so the advisory "say-on-pay" was approved).
• Shareholders ratified the appointment of BDO USA, P.C. as the company’s independent registered public accounting firm for fiscal year 2026 (For: 34,795,850; Against: 1,148,282; Abstentions: 4,430,891).

Key Details

• Meeting date: June 11, 2026; record date: April 17, 2026.
• Shares present/voting power: 40,375,023 shares (~82% of voting power).
• Director election tallies listed per nominee; all three nominees received pluralities of votes cast.
• Auditor ratification passed with ~34.8 million votes in favor.

Why It Matters

• The election results determine the company’s board composition through 2029, affecting oversight and strategic direction.
• The advisory approval of executive compensation indicates shareholder support for pay practices, but is non-binding (the board may consider the result when setting future compensation).
• Ratification of BDO as auditor confirms the firm that will audit Whitehawk’s 2026 financial statements, a routine but important governance matter for investors tracking financial reporting and controls.